Lignamed, LLC
Philadelphia, PA · Medtech · Private
Small molecule therapeutic (LGM2605) administered via ex vivo lung perfusion to reduce oxidative damage in donor lungs before transplantation
- Grants
- $10M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $5.9M
- 2 awards · Health and Human S, NASA
- #105 of 4531 in medtech
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · Igf::ot::igf Development Of Medical Countermeasures To Mitigate And/or Treat Radiation-induced Lung Injury After A Radiological/nuclear Incident | $5,794,476 | |
| Federal contract | National Aeronautics and Space Administration · Igf::ot::igf Lignamed, Llc Is A Drug Development Company With A Fast Track Strategy To Approval Of LGM2605, An Oral Small Molecule For Use As A Radiation Mitigating Agent That Reduces Harmful Effects Of Radiation Exposure Of Normal Tissues. Lignamed Aims To Evaluate LGM2605 As A Mitigator Of Space-radiation Induced Vascular Damage. NASA Missions To Mars Will Expose Astronauts To Solar And Galactic Cosmic Mixed Radiation Including Low Dose. And Proton Radiation, But Data Is Lacking On The Biolog | $125,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Effects of LGM2605 on a Primate Model of Asthma | $277,792 | |
| Federal grant | Department of Health and Human Services · Phase I · Effects of LGM on a Primate Model of Asthma | $277,792 | |
| Federal grant | National Aeronautics and Space Administration · Phase II · LGM2605 as a Mitigator of Space Radiation-Induced Vascular Damage | $754,766 | |
| Federal grant | Department of Health and Human Services · Phase I · Graft-protective properties of LGM2605 in Lung Transplantation | $299,599 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of LGM2605 for use as a device in lung transplant | $299,687 | |
| Federal grant | Department of Health and Human Services · Phase II · IND enabling development of LGM2605 as adjuvant treatment for asthma | $2,964,295 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of LGM2605 for use as a device in lung transplant | $2,356,192 | |
| Federal grant | Department of Health and Human Services · Phase II · IND enabling development of LGM2605 as adjuvant treatment for asthma | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of LGM2605 for use as a device in lung transplant | $916,148 | |
| Federal grant | Department of Health and Human Services · Phase II · IND enabling development of LGM2605 as adjuvant treatment for asthma | $964,295 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 102 | Electrical Geodesics, Inc. | $6.3M | — |
| 103 | Edwards Lifesciences Corp | $6.0M | $307M |
| 104 | BAEBIES, INC. | $5.9M | $77M |
| 105 | Lignamed, LLC | $5.9M | — |
| 106 | TIGER TECH SOLUTIONS INC | $5.9M | — |
| 107 | SILVER LAKE RESEARCH CORPORATION | $5.9M | — |
| 108 | LIBERATING TECHNOLOGIES INC | $5.9M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Process For The Preparation Of (s,s)-secoisolariciresinol Diglucoside And (r,r)-secoisolariciresinol Diglucosideapplication
- Process For The Preparation Of (s,s)-secoisolariciresinol Diglucoside And (r,r)-secoisolariciresinol Diglucosideapplication
- Process For The Preparation Of (s,s)-secoisolariciresional Diglucoside And (r,r)-secoisolariciresinol Diglucosideapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.